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A Novel Triterpenoid Induces Transforming Growth Factor 
Production by Intraepithelial Lymphocytes to Prevent Ileitis
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SOUPHALONE LUANGSAY,* and LLOYD H. KASPER*
*Departments of Medicine and Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire; ‡Institut Pasteur-Institut
Nationel de la Recherche Agronomique, Departement de Parasitologie, Paris, France; and §Trudeau Institute, Saranac Lake, New York
Background & Aims: The loss of homeostasis is a hall-
mark of inflammatory bowel disease. Oral infection of
susceptible mice with Toxoplasma gondii results in an
acute lethal ileitis characterized by increased interferon
, tumor necrosis factor , and inducible nitric oxide
synthase; homeostasis results from transforming
growth factor  production by intraepithelial lympho-
cytes. The synthetic oleanane triterpenoid 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid (CDDO) is a potent an-
ti-inflammatory molecule previously shown in vitro to
suppress the de novo synthesis of inducible nitric oxide
synthase and to induce the transcription and activation
of genes from the transforming growth factor  signal-
ing pathway. Methods: We evaluated the immune re-
sponse in the small intestine and by intraepithelial lym-
phocytes after a single intraperitoneal dose of CDDO at
the time of T. gondii oral infection. We abrogated the
homeostatic effects of CDDO by blocking transforming
growth factor  in vivo. Results: CDDO acid prevented
ileitis development through the global down-regulation
of inflammatory cytokines and chemokines. Total trans-
forming growth factor 1 production by the intraepithe-
lial lymphocytes increased, as did Smad2 expression.
Blocking transforming growth factor  reversed CDDO–
induced protection and prevented the up-regulation of
Smad2 in the small intestine. Conclusions: CDDO acid is
a novel anti-inflammatory molecule capable of prevent-
ing ileitis by activating the transforming growth factor 
signaling pathway in a pathogen-driven ileitis model.
This could represent a new treatment of inflammatory
bowel disease.
The synthetic oleanane triterpenoid 2-cyano-3,12-di-oxooleana-1,9-dien-28-oic acid (CDDO) is a potent
multifunctional molecule. It is a powerful agent for the
induction of differentiation in both malignant and non-
malignant cells.1 It is active as an inhibitor of prolifer-
ation of many malignant or premalignant cells and in-
duces apoptosis by a caspase-8–dependent mechanism.2
Furthermore, it suppresses the abilities of various inflam-
matory cytokines—such as interferon (IFN)-, interleu-
kin 1, and tumor necrosis factor (TNF)-—to induce de
novo formation of the enzymes inducible nitric oxide
synthase (iNOS) and cyclooxygenase 2 in mouse perito-
neal macrophages, rat brain microglia, and colon fibro-
blasts.1,3
CDDO was recently shown to modulate the trans-
forming growth factor (TGF)- signaling pathway by
using an in vitro transfection model. CDDO increases
the expression of TGF-–dependent genes, such as the
type II TGF- receptor and plasminogen activator pro-
tein-1.4 Furthermore, CDDO modulates the Smad sig-
naling pathway through its ability to prolong the acti-
vation of Smad2 induced by TGF-, increases the
binding of Smad3 to the Smad-binding element, and
reverses the inhibitory effects of Smad7.4
Recent studies with human inflammatory bowel dis-
ease (IBD) implicate a role of the TGF- signaling
pathway in the prevention of T-helper 1 (Th1)-type IBD.
Crohn’s disease is an example of a type I inflammatory
condition characterized by increased levels of iNOS,
IFN-, and TNF- and controlled in part by TGF-.5
Enhancing the TGF- signaling pathway has been pro-
posed as a useful therapeutic target for chronic IBD.6 We
have previously shown that homeostatic imbalance be-
tween the synthesis of proinflammatory factors and their
down-regulation leads to severe hyper-IBD in certain
strains of mice after oral infection with Toxoplasma gon-
dii.7 Without any genetic or chemical manipulation, this
model has remarkable similarities to human ileitis with
regard to disease localization, histological findings, and
immunologic profile.7–14 Orally infected mice have dis-
continuous areas of transmural intestinal inflammation,
specifically scattered in the ileum. Histological examina-
tion shows mononuclear and polymorphonuclear cell in-
filtrates in the lamina propria, submucosa, and muscle
layers.7,9,10 There is villous blunting and hemorrhage in
Abbreviations used in this paper: CDDO, 2-cyano-3,12-dioxooleana-
1,9-dien-28-oic acid; DMSO, dimethyl sulfoxide; IEL, intraepithelial
lymphocyte; iNOS, inducible nitric oxide synthase; PCR, polymerase
chain reaction; RPA, ribonuclease protection assay; TGF, transforming
growth factor; Th, T-helper cell; TNF, tumor necrosis factor.
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inflamed small-intestinal mucosa. Moreover, Th1-type T
cells seem to be involved in this pathogen-driven ileitis.
Neutralization of either IFN- or CD4 T cells during
oral T. gondii infection prevents severe necrosis of the
ileum and acute mortality.9,15 Production of IFN- and
TNF- by CD4 T cells isolated from the lamina propria
of mice infected with parasites is thought to mediate this
ileitis.15
Different regulatory mechanisms maintain homeosta-
sis in the infected host. TGF- seems to be an essential
component in the control of the hyperinflammatory pro-
cess in the intestine after oral infection with T. gondii.12
This inflammatory response can also be reversed if the
mice are treated with an inhibitor (such as aminoguani-
dine) of iNOS.
In this study, we show marked antiinflammatory abil-
ity of CDDO in the T. gondii–infected animal model.
CDDO exerts significant protection against the develop-
ment of lethal inflammatory disease as determined his-
tologically but does not result in a toxic effect on the
parasite, because the parasite burden does not change
with CDDO treatment. After CDDO treatment, IFN-
and TNF- messenger RNA (mRNA) levels decrease,
whereas TGF-1 mRNA increases. Total TGF-1 secre-
tion from the small intestine increases with CDDO
treatment. Messages for the proinflammatory chemo-
kines CCL2, CXCL1, and CXCL10 also decrease.
Intestinal intraepithelial lymphocytes (IELs) isolated
from CDDO-treated mice produce increased amounts of
TGF-1 and have increased Smad2 expression. The pro-
tective effect of CDDO is abrogated by pretreatment of
mice with antibodies to TGF-, further suggesting that
CDDO functions by modulating the TGF- and, specif-
ically, the Smad signaling pathway. Blocking TGF-
also prevents the up-regulation of Smad2 mRNA ob-
served in CDDO-treated mice. Triterpenoids such as
CDDO represent a novel class of therapeutic agents that
may act to prevent human inflammatory diseases such as
Crohn’s disease.
Materials and Methods
Mice and Parasites
Female 8–10-week-old C57BL/6 mice obtained from
the Jackson Laboratories (Bar Harbor, ME) were housed under
approved conditions of the Animal Research Facility at Dart-
mouth Medical School. Mice were infected orally by intragas-
tric gavage with 35 cysts from the 76K statin of T. gondii
maintained through passage in CBA/J mice. All experiments
were performed with 4–6 mice per group and were repeated a
minimum of 3 times unless otherwise specified.
CDDO Treatment
Mice received 50 g of CDDO (provided by Michael
B. Sporn, Dartmouth Medical School) in 10% dimethyl sul-
foxide (DMSO; Sigma, St. Louis, MO) in phosphate-buffered
saline (PBS) 0.10 mL intraperitoneally, injected 2 minutes
before infection with the parasite. Control mice received 10%
DMSO in PBS alone. After preliminary testing of doses of 25,
50, and 100 g of CDDO, 50 g was found to be optimal,
with minimal side effects, and this dose was chosen for all
subsequent experiments.
Histology
Intestines were immediately fixed in 10% formalin
overnight, embedded in paraffin, and sectioned. Sections were
stained with H&E and photographed. A histological inflam-
matory score from 0 to 4 was applied in a blinded fashion as
previously described13: 0, no inflammation; 1, slight infiltrat-
ing lymphocytes in the lamina propria with focal acute infil-
tration; 2, mild infiltrating cells in the lamina propria with
increased blood flow and mild edema; 3, diffuse and massive
infiltrating cells leading to disturbed mucosal architecture;
and 4, crypt abscesses and superficial necrosis of the intestinal
villi.
Ribonuclease Protection Assay
Intestines were washed with PBS and placed immedi-
ately in ice-cold Trizol reagent according to the manufacturer’s
protocols (Life Technology, Grand Island, NY). Specific
mRNA expression from whole small intestines was evaluated
with a RiboQuant Multi-probe Ribonuclease Protection Assay
(RPA) System Kit (BD Pharmingen, San Diego, CA) as de-
scribed by the manufacturer. A total of 10 g of RNA from
the intestine was analyzed. Bands were quantified by densito-
metric analysis with NIH Image (National Institutes of
Health, Bethesda, MD) and normalized to L32 and glyceral-
dehyde phosphate dehydrogenase gene expression.
Transforming Growth Factor-1 Enzyme-
Linked Immunosorbent Assay
On day 7 after infection and treatment, intestines were
removed and washed 2 times in PBS; 1-cm pieces of ileum
were removed and cultured for 18 hours in RPMI 1640
(Invitrogen, Carlsbad, CA), 10% fetal calf serum (Hyclone,
Logan, UT), and 1% penicillin/streptomycin with 1% ampho-
tericin B (Fungizone; Invitrogen). Cell supernatants were har-
vested and assayed for total TGF-1 secretion by enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis,
MN).
Purification of Intraepithelial Lymphocytes
IELs were purified as previously described.7 Isolated
IELs (2  106 cells per mouse) were then obtained by Ficoll
centrifugation with Histopaque (d 1.077; Sigma). IELs were
approximately 80% CD8 as determined by fluorescence-
activated cell-sorting analysis. Purified IELs were plated in
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48-well plates at 3  105 cells per 0.5 mL of RPMI 1640
(Invitrogen) with 10% fetal calf serum (Hyclone), 1% peni-
cillin/streptomycin, and 1% amphotericin B. Cell supernatants
were collected 14 hours after infection and assayed for TGF-1
secretion by enzyme-linked immunosorbent assay (R&D Sys-
tems).
Two-Step SYBR Green Quantitative Real-
Time Polymerase Chain Reaction
A total of 0.5 to 2.0 g (within each experiment,
the same quantity of mRNA was used) of deoxyribonucle-
ase-treated (Ambion, Austin, TX) mRNA was reverse-tran-
scribed with SuperScript II reverse transcriptase (Invitro-
gen). A total of 100 ng of complementary DNA was
amplified with the SYBR green core reagents (AP Biosys-
tems, Foster City, CA) on a Bio-Rad (Hercules, CA) iCycler.
Plasmid controls of all amplicons were constructed by using
the TA cloning kit (Invitrogen) and were run in parallel with
experimental samples. Relative expression was expressed by using
the 	CT method, where CT  2
(exp
-actin)1000. Previously
published primers were as follows—iNOS: 5-CATTGGA-
AGTGAAGCGTTTCG-3, 5-CAGCTGGGCGCGACAAA-
CCT-316; IFN-: 5-GCATTCATGAGTATTGCCAAG-3,
5-GGTGGACCACTCGGATGA-3; TNF-: 5-CATCT-
TCTCAAAATTCGAGTGACAA-3, 5-TGGGAGTAGACA-
AGGTACAACCC-3; -actin: 5-AGAAAGGGTCGTGC-
GTGAC-3, 5-CAATAGTGATGACCTGGCCGT-317; and
Smad2: 5-GAAACCTGCATTCTGGTGTT-3, 5-CGAGTT-
TGATGGGTCTGTGA-3.
Immunoblots
Purified IELs were prepared for protein analysis by
using standard techniques from 4–6 mice per group, repeated
2 times. A total of 50 g of protein was loaded per lane. Gels
were transferred onto Bio-Rad ImmunoBlot Nitrocellulose
membranes. Transferred blots were stained with ponceau red
to ensure equal loading of lanes as well as efficient transfer.
Immunoblots were probed with Smad2 antibody (Zymed,
South San Francisco, CA) and -actin (Sigma). Anti-mouse
(Sigma) and anti-rabbit (Santa Cruz Biotechnology, Santa
Cruz, CA) secondary antibodies conjugated to horseradish
peroxidase were visualized by using ECL-Plus chemilumines-
cence (Amersham Biosciences, Piscataway, NJ).
In Vivo Blocking Studies
A total of 1 mg of TGF-–blocking antibody (1d11;
provided by Genzyme, Boston, MA) was administered intra-
peritoneally on days 
1, 0, 2, 4, and 6 (200 g/100 L per
mouse; 6 mice per group). MOPC21 isotype control antibody
(Sigma) was given in parallel as a negative control. Antibody-
treated and control mice that achieved the animal welfare–
approved end point for termination at day 6 after infection
were scored for histological evidence of inflammation.
Statistical Analyses
Groups were compared by using Prism (GraphPad, San
Diego, CA) statistical software’s unpaired t test; significance
was expressed as P  0.05, P  0.01, or P  0.001.
Results
Histological Analysis of CDDO Protection
Because CDDO was previously shown to alter the
expression of key proinflammatory and anti-inflamma-
tory cytokines, we evaluated the effects of varying doses
of CDDO for the prevention of an acute pathogen-driven
ileitis by examining the histology of the mouse intestine
after oral infection with T. gondii. Mice orally infected
with a lethal dose of 35 cysts followed 2 minutes later
with an intraperitoneal treatment of 50 g of CDDO or
10% DMSO alone, the vehicle control, were assayed for
inflammation. Histological analysis performed 7 days
after infection showed the characteristic histopathology
of shortened villi, swollen lamina propria packed with
inflammatory cells, necrosis, and hemorrhage evident at
the tip of the villi (Figure 1A). In contrast, mice treated
with 50 g of CDDO displayed a normal intestinal
mucosa; some intestines showed a mild infiltration of
lymphocytes, but there was no evidence of major inflam-
mation and necrosis (Figure 1A). Histological scoring
showed significant protection with CDDO treatment
(P  0.001; Figure 1B). This protection was observed
only when treatment was delivered at the time of infec-
tion, because CDDO did not protect when administered
24, 48, or 72 hours after infection (data not shown).
Similarly, multiple doses of CDDO delivered throughout
the infection did not provide any further protection
against the development of this inflammatory disease
(data not shown). Treatment with CDDO or DMSO in
the absence of infection had no effect on the integrity of
the intestinal mucosal surface (Figure 1A). A single dose
of 50 g of CDDO was the most effective and had no
observable side effects; 25 g was not effective at pre-
venting ileitis, and 100 g had a side effect of swelling
of the small bowel and adipocyte accumulation along the
basal layer of the mucosal surface but had no evidence of
inflammation or necrosis (data not shown). Daily treat-
ment with 50 g of CDDO at days 
2, 
1, and 0
resulted in the same outcome as a single dose of 50 g
of CDDO; in contrast, treatment of mice with 50 g of
CDDO 1 and 2 days after oral infection with T. gondii
did not protect mice against ileitis (100% of mice suc-
cumbed to ileitis). Because 50 g of CDDO just before
infection was the most effective dose at preventing ileitis,
this dose was chosen for the remainder of the study.
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Parasite Viability
Parasite viability ruled out a possible direct toxic
effect of CDDO on the microorganism. After challenge
with a sublethal dose (25 parasites per mouse), there was
no statistical difference in the brain cyst load between
mice treated with CDDO and those treated with DMSO
(Figure 1C). Additionally, polymerase chain reaction
(PCR) amplification of the B1 gene specific to T. gondii
at day 7 after infection showed no difference in parasite
burden between intestines obtained from mice that had
received CDDO or DMSO (data not shown).
Chemokine Expression
After T. gondii infection, CD4 T cells from the
periphery migrate to the lamina propria and synergize
with infected epithelial cells to induce the secretion of
several inflammatory chemokines, including CCL1,
CCL2, CCL3, CXCL1, and CXCL10.15 To determine
whether CDDO treatment could alter the chemokine
profile in the small intestine, RNA from day 7 treated/
infected mice was analyzed by RPA. There was a signif-
icant down-regulation of CCL2, CXCL1, and CXCL10
(P  0.01; Figure 2). In the absence of infection, CDDO
treatment did not affect chemokine expression in the
small intestine (data not shown). The differences between
chemokine mRNA levels peaked at day 7 after infection,
as previously described,18 with very low levels of chemo-
kine secretion at earlier time points (days 1, 3, and 5;
data not shown).
Cytokine Expression
The overproduction of Th1-type cytokines is a
hallmark of human IBD and T. gondii–induced ileitis in
mice.9,15,19–21 CDDO was previously shown in vitro to
suppress the ability of inflammatory cytokines, including
IFN-, interleukin 1, and TNF-, to induce de novo
formation of iNOS in mouse peritoneal macrophages.1,3
At day 7 after infection, CDDO-treated and infected
mice produced significantly less mRNA for both IFN-
and TNF- compared with DMSO-treated and infected
mice, as determined by an RPA (Figure 3A). We con-
firmed a significant decrease in IFN- mRNA with
SYBR green quantitative real-time PCR, a more sensi-
tive method for mRNA detection (Figure 3B). DMSO
and CDDO alone did not induce cytokine production
(data not shown). Increases in cytokine profiles from
Figure 1. CDDO prevents acute ileitis. (A) Ileum sections treated with
either CDDO or DMSO and obtained from naive and day 7 infected
mice showed a decrease in inflammation (magnification, 200). (B)
CDDO treatment with infection (F) significantly reduced the inflamma-
tion score compared with DMSO with infection (}) (P  0.001);
neither DMSO alone (‚) nor CDDO alone (E) caused inflammation.
Histological scoring of ileum sections—where 0 indicates no inflam-
mation; 1 indicates slight infiltrating lymphocytes in the lamina pro-
pria with focal acute infiltration; 2 indicates mild infiltrating cells in the
lamina propria with increased blood flow and mild edema; 3 indicates
diffuse and massive infiltrating cells leading to disturbed mucosal
architecture; and 4 indicates crypt abscesses and superficial necrosis
of the intestinal villi13—showed statistically significant protection
against inflammation and necrosis with CDDO treatment; the line
represents the mean (***P  0.001). (C) The parasite burden, as
attested to by the brain cyst load  SEM after a sublethal dose of T.
gondii, showed no statistical difference between infected groups that
received CDDO or DMSO. Parasite burden data are from 1 represen-
tative experiment.
Figure 2. Modification of chemokine expression in the small intestine
by CDDO. Ribonuclease protection assay of ileum samples showed a
significant down-regulation in mRNA expression of inflammatory che-
mokines with CDDO treatment compared with DMSO; 1 representa-
tive experiment is shown. The error bars are  SEM; **P  0.01;
***P  0.001.
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infected mice were optimal at day 7 after infection;
earlier time points (days 1, 3, and 5) showed no detect-
able up-regulation in cytokine levels in the infected
control groups (data not shown). Because mRNA for
TGF-1 increased, as determined by an RPA (Figure
3A), infected small intestines from mice treated with
CDDO were cultured, and the supernatants were mea-
sured for total TGF-1 secretion by enzyme-linked im-
munosorbent assay. CDDO treatment significantly in-
creased the total TGF-1 secretion at day 7 after
infection (Figure 3C).
Effects of CDDO on Cytokine Expression by
Intestinal Intraepithelial Lymphocytes
TGF-1 production is essential for maintaining
intestinal homeostasis in human IBD and in the T.
gondii–induced acute ileitis model.6,12,22–24 TGF-1
mRNA and total TGF-1 protein were up-regulated in
the intestine and peaked at day 7 in mice treated with
CDDO and infected (Figure 3A and C). IELs were pre-
viously shown to be essential for maintaining gut ho-
meostasis after T. gondii infection. The principal mech-
anism for this protective effect is via the production of
TGF-1.12,22 Culture supernatants of IELs purified from
day 7 infected and CDDO-treated mice produced signif-
icantly more total TGF-1 than those from infected and
DMSO mice (P  0.001; Figure 4A). CDDO treatment
of uninfected control mice did not alter the TGF-
production compared with DMSO-treated mice; the dif-
ference in TGF- production was observed early after
infection but peaked at day 7 after infection/treatment
compared with earlier time points (day 1: DMSO plus
infection, 48.75  1.02 pg/mL; CDDO plus infection,
62.29  1.05 pg/mL; day 4 after infection: DMSO plus
infection, 59.51  1.05 pg/mL; CDDO plus infection,
49.3  1.04 pg/mL). There was no difference in the
production of IFN- and TNF- by the IELs isolated
from the CDDO- or DMSO-treated and infected IELs at
day 7 after infection (Figure 4B).
CDDO Modulates Smad2 Expression by the
Small Intestine and by the Intestinal
Intraepithelial Lymphocytes
TGF-1 induced by CDDO was previously shown
to modulate the Smad signaling pathway in vitro.4 To
determine whether CDDO could alter Smad2, 3, 4, and
7 expression early in the whole intestine, we performed
RNA analysis. Of the Smads tested, only Smad2 analysis
showed a significant difference in mRNA expression;
Smad2 mRNA increased at day 1 after infection (Figure
5A) and continued to increase at day 7 after infection
(Figure 5B). No statistical difference in Smad3 or Smad4
expression was observed among the CDDO-treated and
DMSO-treated groups (data not shown). Moreover, IELs
isolated from infected and CDDO-treated mice expressed
high levels of Smad2 protein 1 day after infection (Figure
6); CDDO alone did not increase Smad2 protein expres-
sion (data not shown).
Figure 3. Modification of cytokine expression in the small intestine by
CDDO. Ribonuclease protection assay showed that CDDO treatment
resulted in a statistically significant decrease in mRNA for TNF- and
IFN- (A). TGF-1 levels significantly increased compared with DMSO;
(B) SYBR green quantitative real-time PCR (QRTPCR) resulted in a
statistically significant decrease of IFN- production with CDDO treat-
ment compared with DMSO. One representative experiment is shown
(mean SEM). (C) TGF-1 secretion of ileum pieces by enzyme-linked
immunosorbent assay showed a significant increase in total TGF-1 in
intestines from CDDO-treated mice on day 7 after infection (mean 
SEM; n  3 mice per group repeated 2 times). *P  0.05; **P 
0.01; ***P  0.001.
Figure 4. Cytokine expression from IELs after CDDO treatment. (A)
Supernatants from ex vivo–cultured CDDO-treated IELs contained
increased levels of total TGF-1 compared with DMSO; data are
representative of 2 independent experiments (mean  SEM). (B)
SYBR green quantitative real-time PCR showed that IELs from CDDO-
treated and infected mice did not express reduced mRNA for IFN- and
TNF- compared with IELs from DMSO-treated mice; 1 representative
experiment is shown (mean  SEM).
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CDDO Protection Is Dependent on TGF-
To determine whether CDDO’s protection
against inflammation required TGF-, mice were treated
in vivo with TGF-–blocking antibody (Genzyme
1d11). Treatment with 1 mg of anti–TGF-–blocking
antibody abrogated the protection mediated by CDDO.
The intestines of mice treated with anti–TGF- and
CDDO developed severe necrosis, a loss of villi architec-
ture, and increased inflammatory infiltrates and hemor-
rhages. Quantification of the inflammation showed no
significant protection against ileitis after blocking
TGF- (Figure 7A). To confirm that Smad2 mRNA
up-regulation by CDDO was essential for the protection
observed in this model of inflammation, mRNA analysis
of Smad2 was performed from the small intestines with
TGF- blocked. As expected, Smad2 mRNA from in-
fected mice treated with CDDO and the isotype control
showed a significant increase in Smad2 mRNA compared
with the DMSO and isotype control (P  0.001). Block-
ing TGF- prevented this increase in Smad2 mRNA in
CDDO-treated mice (Figure 7B).
Discussion
In this study, we show the novel in vivo effect of
CDDO at suppressing pathogen-driven intestinal in-
flammation. Treatment of T. gondii–infected mice with a
single intraperitoneal injection of CDDO at the time of
infection impairs the development of an acute lethal
ileitis. CDDO has no toxic effect on either parasite
multiplication or entry into the host cells.
CDDO’s ability to prevent this pathogen-driven acute
ileitis is dependent on TGF- production. Previous stud-
ies implicate TGF- as an essential component in the
control of the hyperinflammatory process in the gut after
oral infection with this parasite.12 The protective effect of
CDDO is abolished by blocking TGF-. We show that
IELs, which comprise a major compartment of the gut-
associated lymphoid tissue, respond to CDDO exposure
and up-regulate the production of TGF-. Treatment of
CBA/J mice (although these mice can become infected
with the parasite, they do not succumb to the same
inflammation as C57BL/6 mice) with antibody to TGF-
turns their resistant phenotype into a susceptible one.12
In susceptible C57BL/6 mice, adoptive transfer of anti-
gen-primed IELs that produce TGF- prevents the in-
flammatory process.12 Blocking TGF- abolishes adop-
tive protection in this model of pathogen-driven ileitis.
In this study, treatment with anti–TGF- worsened the
inflammation. However, we showed that the CDDO
could not overcome the absence of TGF-. Additionally,
Figure 5. Messenger RNA expression of Smad2 from the small intes-
tine from CDDO-treated mice. (A) SYBR green quantitative real-time
PCR of Smad2 mRNA in the intestine increased after CDDO treatment
on day 1 after treatment/infection compared with DMSO; data are
from 1 representative experiment (mean  SEM). ***P  0.0001.
(B) Quantitative real-time PCR for Smad2 in the intestine showed an
increase of Smad2 mRNA at day 7 after infection; data are from 1
representative experiment (mean  SEM; **P  0.001).
Figure 6. Smad2 protein expression by IEL from CDDO-treated mice.
CDDO treatment and infection increases Smad2 protein expression
as determined by Western blot analysis compared with DMSO and
infection; data are from 1 representative experiment.
Figure 7. Histological analysis after blocking TGF-. Blocking TGF- in
vivo abrogated CDDO’s protection against T. gondii–induced inflam-
mation, as determined by histological score, compared with DMSO.
DMSO and isotype control (‚), CDDO and isotype control (E), DMSO
and anti–TGF- (Œ), CDDO and anti–TGF- (F). Results are from 6
mice per group; lines represent means; ***P  0.001 (A). Blocking
TGF- prevents the ability of CDDO to up-regulate Smad2 mRNA at day
7 after infection/treatment. ***P  0.0001 between DMSO plus
isotype control and CDDO plus isotype control (B); data are from the
mice used in (A) (mean  SEM).
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our data show that TGF- and Smad2 are up-regulated
in response to CDDO. Taken together, it is reasonable to
anticipate that if the homeostatic balance in the gut is
disturbed by the blocking antibody and if CDDO cannot
rescue these mice, then CDDO is working through
TGF-.
Synthesis of TGF- by antigen-primed IELs inhibits
IFN- production by lamina propria CD4 T cells,15 the
principal cell type responsible for the production of
TNF- and IFN- in the intestine. When IELs were
assayed for a possible reduction in IFN-, TNF-, and
iNOS mRNA, there was no significant reduction, further
suggesting that the CD4 T cells from the lamina pro-
pria could be the cell type targeted by the increase in
TGF-1 production.
Although our study focused on the IEL population
because they have been previously shown to be important
regulators of intestinal homeostasis, IELs may not be the
unique cell type targeted by CDDO treatment. Our
unpublished in vitro observation suggests that CDDO
may be able to induce TGF- signaling in another
TGF-–producing cell, the enterocytes. It is possible
that these other cellular players may increase the protec-
tive effect of CDDO by further inducing TGF- produc-
tion.
Previously published data with CDDO further impli-
cate the importance CDDO’s ability to target TGF-1
production and specifically the Smad system, because
CDDO increases the binding of Smad3 to its CAGA
binding element and also increases the phosphorylation
of Smad2.4 We showed that CDDO increases the expres-
sion of Smad2 in the whole intestine and more specifi-
cally among the IEL population but that the up-regula-
tion of Smad2 is early after the induction of
inflammation, further suggesting that CDDO’s primary
effects are early after treatment. We also show that the
up-regulation of Smad2 mRNA by the small intestine
can be observed at day 7, a time when the ileitis score is
high among the untreated groups. An inability to induce
the effects of TGF- through a defect in the Smad
signaling pathway is crucial in the development of hu-
man IBD such as Crohn’s disease.6,23 Smad2- and Smad4-
deficient mice are embryonic lethal, further implicating
these proteins as essential for normal immune func-
tion.25–27
CDDO has a demonstrably fast half-life of 30 minutes,
and this suggests that the action of this compound is
immediate and perhaps alters the early immune response
in the mucosa. Treatment with CDDO after T. gondii
infection does not protect against ileitis, presumably
because the homeostatic balance in the intestine has
already been altered because of the infection. CDDO
treatment just before infection could maintain the ho-
meostasis in the intestine, as indicated by a decrease in
inflammation and a decrease in chemokine expression.
TGF- induction has been previously shown to decrease
the chemokine expression after T. gondii infection.10,12
Because CDDO treatment alters the chemokine expres-
sion in the intestine, this effect could be explained by the
early induction of TGF- by CDDO. Early secreted
chemokines play an essential role in monocyte and neu-
trophil attraction and activation. A lack of chemokine
secretion, as observed with CDDO treatments, could lead
to a defect in lymphocyte migration and activation to the
site of injury, as seen in the histology.
In addition to a decrease in chemokine secretion,
TGF- induction by CDDO could explain the decrease
in inflammatory cytokines in the intestine. In this and
other models of inflammation, TGF- production by T
cells can shift the homeostatic balance away from the
production of proinflammatory cytokines such as IFN-,
which, in turn, begin the inflammatory cascade.12,14,15,28
CDDO prevents overproduction of the Th1-related in-
flammatory molecules and cytokines such as nitric oxide
and IFN-. The ability of CDDO to down-regulate
iNOS was evaluated in a series of in vitro experiments
that used tissue cultured cells (data not shown); however,
in vivo, CDDO did not down-regulate iNOS mRNA.
These studies are the first in vivo reports of the actions of
this novel drug; therefore, it is not surprising that
CDDO may act differently in vivo than in vitro.
CDDO and DMSO alone did not induce mRNA for
Th1-type cytokines. Furthermore, there may be a dis-
crepancy between the amount of IFN- required to
control the parasite and the amount required to induce
ileitis; this may explain why the parasite burden was not
affected by the CDDO treatment. The decreased produc-
tion of those inflammatory molecules correlated with a
significant increase in TGF- mRNA and protein by
cells in the small intestine, including IELs, which have
been shown to be important regulators of this pathogen-
driven inflammatory pathology.12 Thus, the enhance-
ment of TGF- levels in mice treated with CDDO might
explain the decrease in observed intestinal IFN- and
TNF-.6,12,14,15,23,28 CDDO did not significantly reduce
TNF- mRNA in the small intestine as measured by
quantitative real time PCR, even though with the RPA
there was a decrease in mRNA. This difference in
mRNA is presumably due to the decreased sensitivity of
quantitative real-time PCR, because all PCR primers
were previously published and control plasmids were run
in parallel with all PCR reactions.
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In summary, CDDO seems to induce TGF- secretion
in the intestine, at least by the IELs. This early induction
of TGF- seems to decrease cytokines and chemokines
though a downstream effect of TGF-. Thus, novel
therapeutics such as CDDO that target this pathway may
represent a new approach for the treatment of human
inflammatory diseases such as Crohn’s disease.6
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